Seqirus Gains FDA Approval for Flucelvax for 2026–2027 Influenza Season

Seqirus Inc. has secured its annual FDA approval for Flucelvax (STN: 125408) for the 2026–2027 influenza season, with the approval letter dated July 1, 2026, a cadence that reflects sustained regulatory confidence in the company's Madin-Darby Canine Kidney (MDCK) cell-based manufacturing platform. For QA directors and plant heads managing seasonal vaccine production, the approval confirms that Seqirus's process validation and strain-update submissions met CBER's annual review threshold without supplemental delay.

The cell-based production model underlying Flucelvax carries distinct GMP implications relative to egg-based manufacturing. MDCK platforms eliminate the egg-adaptation step that can introduce antigenic drift in egg-derived strains, a variable that has complicated lot release decisions and post-market surveillance in prior seasons. From a 21 CFR Part 610 standpoint, cell-derived lots must still satisfy potency, sterility assurance, and identity testing requirements, but the substrate consistency of a qualified cell bank offers more predictable in-process controls than embryonated egg supply chains subject to agricultural variability.

Flucelvax is approved for active immunization against influenza A subtypes and type B strains contained in the seasonal formulation, for persons six months of age and older. The March 23, 2026 approval letter, issued ahead of the July cycle, suggests a supplemental submission was reviewed and cleared earlier in the calendar year, though the source documents do not specify the scope of that action. Regulatory affairs leads tracking Seqirus's submission history will note that annual approvals have been issued consistently on or around July 1 since at least 2024, indicating a stable post-approval change management process aligned with WHO strain selection timelines.

For manufacturers benchmarking their own seasonal biologics programs against industry practice, Seqirus's approval record under ICH Q10 pharmaceutical quality system principles illustrates how a mature cell-based platform can sustain annual regulatory cycles with minimal disruption. The consistency of the approval timeline is itself a process signal: it suggests that comparability assessments for annual strain updates are well-characterized and that CBER's review of manufacturing data has not surfaced outstanding chemistry, manufacturing, and controls deficiencies.

The next measurable checkpoint for Seqirus will be lot release data for the 2026–2027 season, which will indicate whether MDCK-derived yields met projected fill volumes ahead of the Northern Hemisphere distribution window.

Source: FDA Vaccines, Blood and Biologics product page via What's New Vaccines Blood Biologics RSS Feed, July 2, 2026.